The appointment signals board strengthening with a capital markets-savvy executive, potentially positioning for future financings or strategic moves. Monitor for increased engagement from RA Capital or similar investors given Dable's ties.
TYRA drugs
TYRA drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 17 $35.56entry
- T+1 · 7mo ago −3.35%α −3.15% · $34.37
- T+5 · 7mo ago +5.71%α +5.15% · $37.59
- T+20 · 6mo ago +2.67%α −2.70% · $36.51
- T+60 · 4mo ago −7.54%α −13.68% · $32.88
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Tyra Biosciences appointed Habib J. Dable to its board of directors as a Class II director, effective April 16, 2026. Dable, a seasoned biopharma executive and current advisor at RA Capital, was granted stock options to purchase 44,400 shares. The move expands the board from nine to ten members.
Key Facts
- Habib J. Dable appointed to the board of directors effective April 16, 2026
- Board size increased from nine to ten members
- Dable is a former CEO of Acceleron Pharma and holds board roles at multiple biotech firms
- Granted options to purchase 44,400 shares of common stock, vesting over 36 months
- Board determined Dable is independent under Nasdaq rules
Financial Impact
Approximately $1.1 million in initial equity grant (based on 44,400 options at $24.70/share, TYRA's implied price at time of grant)
Risk Factors
- Limited immediate operational impact from director appointment
- Equity grant contributes to share dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-160347 |
| Document: 0001193125-26-160347-index-headers.html | 0001193125-26-160347 |
| Document: 0001193125-26-160347-index.html | 0001193125-26-160347 |
| Document: 0001193125-26-160347.txt | 0001193125-26-160347 |
Track record
13 reports on TYRA
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +20.37% at T+60 after the Jun 26, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $21.00 Now $19.74 −6.00% settles Nov 17
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $21.75 to $21.53 Now $19.74 −9.24% ▼ −1.03% −0.32% vs SPY
- Sep 21, 20268w ago SC 13G Neutral 4/10 Entry $25.57 to $21.98 Now $19.74 −22.80% ▼ −14.04% −12.85% vs SPY
- Sep 17, 20268w ago Insider Cluster Bullish 8/10 Entry $25.73 to $21.76 Now $19.74 −23.28% ▼ −15.43% −16.70% vs SPY
- Sep 14, 20269w ago S-3ASR Neutral 3/10 Entry $25.07 to $25.65 Now $19.74 −21.26% ▲ +2.31% +2.21% vs SPY
- Sep 9, 20269w ago 8-K Bullish 6/10 Entry $22.01 to $24.35 Now $19.74 −10.31% ▲ +10.63% +11.73% vs SPY
- Aug 4, 202614w ago 424B5 Bearish 6/10 Entry $25.71 to $25.30 Now $19.74 +23.22% ▲ +1.59% +1.95% vs SPY
- Jun 26, 202620w ago 144 Bearish 6/10 Entry $32.11 to $30.86 Now $19.74 +38.52% ▲ +3.89% +5.28% vs SPY
- May 13, 202626w ago 8-K Mixed 5/10 Entry $36.19 to $33.78 Now $19.74 −45.45% ▼ −6.66% −5.50% vs SPY
- Apr 20, 202630w ago 3 Neutral 2/10 Entry $36.69 to $35.06 Now $19.74 −46.20% ▼ −4.44% −5.53% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers